Detailed financial statements for Curis, Inc. (CRIS): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Analysis Summary
Curis, Inc. reported revenue of $9.4M in the most recent fiscal year, growing at a 5-year CAGR of -2.7%.
Trailing-twelve-month margins: gross margin 99.3%, operating margin -8.3%, net margin -490.3%.
At the current price of $1.12, CRIS has negative trailing earnings (P/E not meaningful) and an ROE of -10.35%. Market capitalisation stands at $2M.
Balance sheet quality for CRIS: current ratio of 0.5, net cash position of $3.4M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.9M | $10.4M | $10.0M | $10.8M | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M |
| Cost of Revenue | $399000 | $496000 | $563000 | $503000 | $534000 | $533000 | $257000 | $212000 | $98000 | $45000 |
| Gross Profit | $7.1M | $9.4M | $9.9M | $9.5M | $10.3M | $10.1M | $9.9M | $9.8M | $10.8M | $9.4M |
| Research & Development | $31.6M | $33.3M | $24.4M | $22.3M | $23.1M | $34.9M | $43.3M | $39.5M | $38.6M | $28.3M |
| Selling, General & Admin | $15.6M | $25.8M | $14.8M | $11.6M | $12.1M | $17.3M | $19.6M | $18.6M | $16.8M | $14.0M |
| Operating Expenses | $47.2M | $59.2M | $39.2M | $33.9M | $35.2M | $52.2M | $62.9M | $58.1M | $55.4M | $42.3M |
| Operating Income | -$58.0M | -$49.8M | -$29.3M | -$24.4M | -$24.9M | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$32.9M |
| EBITDA | -$57.4M | -$49.1M | -$28.5M | -$27.2M | -$24.7M | -$40.8M | -$51.7M | -$45.1M | -$42.6M | -$5.2M |
| Interest Expense | $2.8M | $4.0M | $3.9M | $4.8M | $5.1M | $4.5M | $4.8M | $2.0M | $615000 | $2.2M |
| Pre-tax Income | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| EPS | $-900.00 | $-3575.20 | $-393.40 | $-387.40 | $-245.80 | $-198.40 | $-242.80 | $-179.20 | $-137.60 | $-11.60 |
| EPS (Diluted) | $-900.00 | $-3575.20 | $-393.40 | $-387.40 | $-245.80 | $-198.40 | $-242.80 | $-179.20 | $-137.60 | $-11.60 |
| Shares Outstanding (Diluted) | $66392 | $14913 | $82795 | $82951 | $121675 | $228922 | $233481 | $264664 | $315314 | $658201 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $26.0M | $38.3M | $23.6M | $15.4M | $129.6M | $40.0M | $19.7M | $26.7M | $20.0M | $5.1M |
| Short-term Investments | $18.4M | $21.9M | $634000 | $5.1M | $38.9M | $75.9M | $66.0M | $29.7M | 0 | 0 |
| Receivables | $2.5M | $3.1M | $2.9M | $3.2M | $3.0M | $3.2M | $3.0M | $2.8M | $3.3M | 0 |
| Inventory | -$1.3M | 0 | -$827000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $46.9M | $64.3M | $27.1M | $25.0M | $172.8M | $122.4M | $92.1M | $60.9M | $26.4M | $6.9M |
| Property, Plant & Equipment | $413000 | $366000 | $267000 | $303000 | $7.2M | $6.3M | $5.1M | $3.5M | $3.4M | $2.0M |
| Goodwill | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M | $9.0M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $57.8M | $73.8M | $37.4M | $35.1M | $204.4M | $162.3M | $108.8M | $77.3M | $41.3M | $20.0M |
| Accounts Payable | $5.9M | $5.4M | $2.9M | $4.5M | $4.2M | $6.4M | $3.2M | $3.2M | $3.0M | $5.6M |
| Short-term Debt | $4.9M | $5.9M | $6.9M | 0 | $557000 | 0 | 0 | 0 | 0 | $1.2M |
| Total Current Liabilities | $8.6M | $14.1M | $6.4M | $6.5M | $10.1M | $13.4M | $10.0M | $22.0M | $19.0M | $14.1M |
| Long-term Debt | $14.9M | $35.7M | $28.6M | 0 | $334000 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $28.5M | $49.8M | $41.9M | $69.0M | $73.7M | $71.6M | $62.3M | $57.6M | $47.3M | $14.5M |
| Retained Earnings | -$898.9M | -$952.3M | -$984.8M | -$1.02B | -$1.05B | -$1.09B | -$1.15B | -$1.20B | -$1.24B | -$1.25B |
| Total Equity | $29.3M | $24.0M | -$4.5M | -$33.9M | $130.7M | $90.7M | $46.6M | $19.7M | -$6.0M | $5.5M |
| Total Debt | $19.9M | $41.6M | $35.5M | $166000 | $7.7M | $5.0M | $3.9M | $2.8M | $3.0M | $1.6M |
| Net Debt | -$24.6M | -$18.7M | $11.2M | -$20.4M | -$160.8M | -$110.8M | -$81.7M | -$53.5M | -$17.0M | -$3.4M |
| Working Capital | $38.3M | $50.2M | $20.8M | $18.5M | $162.7M | $108.9M | $82.1M | $38.9M | $7.4M | -$7.2M |
Cash Flow (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$60.4M | -$53.3M | -$32.6M | -$32.1M | -$29.9M | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M |
| Depreciation & Amortization | $193000 | $235000 | $177000 | $125000 | $144000 | $158000 | $233000 | $255000 | $187000 | $169000 |
| Stock-based Compensation | $4.3M | $5.4M | $3.9M | $2.7M | $2.7M | $5.3M | $6.8M | $6.0M | $5.9M | $4.0M |
| Change in Working Capital | $1.9M | -$723000 | -$1.5M | -$1.6M | $1.0M | $1.0M | -$6.8M | $2.8M | -$3.7M | $1.8M |
| Operating Cash Flow | -$35.8M | -$48.4M | -$30.1M | -$26.2M | -$25.7M | -$37.6M | -$54.3M | -$38.4M | -$39.6M | -$27.2M |
| Capital Expenditure | -$329000 | -$188000 | -$85000 | -$41000 | -$677000 | 0 | -$416000 | 0 | 0 | 0 |
| Acquisitions | $329000 | $188000 | $85000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$36.1M | -$48.5M | -$30.1M | -$26.2M | -$26.4M | -$37.6M | -$54.8M | -$38.4M | -$39.6M | -$27.2M |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +31.5% | +5.4% | -4.1% | +8.3% | -1.7% | -4.6% | -1.4% | +8.8% | -13.4% | |
| Net Income Growth (YoY) | +11.7% | +38.9% | +1.3% | +6.9% | -51.9% | -24.7% | +16.3% | +8.5% | +82.5% | |
| EPS Growth (YoY) | -297.2% | +89.0% | +1.5% | +36.6% | +19.3% | -22.4% | +26.2% | +23.2% | +91.6% | |
| Shares Change (YoY) | -77.5% | +455.2% | +0.2% | +46.7% | +88.1% | +2.0% | +13.4% | +19.1% | +108.7% | |
| FCF Growth (YoY) | -34.3% | +37.9% | +12.9% | -0.6% | -42.4% | -45.5% | +29.8% | -2.9% | +31.2% | |
| Gross Margin | 94.7% | 95.0% | 94.6% | 95.0% | 95.1% | 95.0% | 97.5% | 97.9% | 99.1% | 99.5% |
| Operating Margin | -771.1% | -502.7% | -281.3% | -243.5% | -229.8% | -395.0% | -521.7% | -482.2% | -408.3% | -348.4% |
| EBITDA Margin | -763.1% | -496.2% | -273.0% | -271.6% | -227.7% | -383.2% | -508.4% | -450.4% | -390.3% | -55.4% |
| Net Margin | -802.6% | -538.7% | -312.4% | -321.3% | -276.0% | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% |
| FCF Margin | -480.1% | -490.4% | -289.1% | -262.4% | -243.8% | -353.3% | -538.8% | -383.5% | -362.7% | -288.1% |
| Effective Tax Rate | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Per-Share Data (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-544.34 | $-3255.08 | $-364.15 | $-316.40 | $-217.10 | $-164.33 | $-234.51 | $-145.22 | $-125.47 | $-41.33 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $66392 | $14913 | $82795 | $82951 | $121675 | $228922 | $233481 | $264664 | $315314 | $658201 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | -1035.26% |
| Return on Invested Capital | -567.17% |
| Return on Assets | -111.51% |
| Gross Margin | 99.28% |
| Operating Margin | -833.40% |
| Net Margin | -490.33% |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 0.49 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -92.32 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -6.84 | -0.39 | -0.70 | -1.76 | -13.33 | -9.60 | -0.91 | -1.42 | -0.44 | -1.70 |
| P/B | 13.97 | 0.87 | -5.08 | -1.66 | 3.05 | 4.81 | 1.10 | 3.43 | -3.22 | 2.38 |
| P/S | 54.33 | 2.11 | 2.19 | 5.64 | 36.79 | 40.93 | 5.05 | 6.73 | 1.77 | 1.38 |
| Gross Margin | 94.7% | 95.0% | 94.6% | 95.0% | 95.1% | 95.0% | 97.5% | 97.9% | 99.1% | 99.5% |
| Operating Margin | -771.1% | -502.7% | -281.3% | -243.5% | -229.8% | -395.0% | -521.7% | -482.2% | -408.3% | -348.4% |
| Net Margin | -802.6% | -538.7% | -312.4% | -321.3% | -276.0% | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% |
Related companies: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explore sector: Healthcare · Biotechnology
More sections of CRIS: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks